Researchers are exploring the potential of drugs like lixisenatide (originally for diabetes) to treat PD

Studies show a link between type 2 diabetes (T2D) and Parkinson’s disease, as both conditions share factors like insulin resistance and inflammation. Lixisenatide belongs to a class of drugs called GLP-1 receptor agonists, which help with blood sugar control in diabetes. More recently, these drugs have shown promise in protecting brain cells, leading to their study in neurodegenerative diseases like PD. While lixisenatide was approved for T2D treatment in 2016, it was later discontinued for business reasons. Now, research is focusing on how it could help slow the progression of PD by protecting neurons. Early trials have shown that lixisenatide can slow motor symptoms in people with early-stage PD, though more research is needed to confirm its long-term benefits. Side effects like nausea and vomiting were reported, which could impact its use. Although results are promising, larger studies are needed to better understand how lixisenatide could be used in treating Parkinson's disease and whether it can truly offer long-term protection for the brain.